Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Rituximab 70Cyclophosphamide 46fludarabine 21fludarabine phosphate 20Mycophenolic Acid 20Etoposide 18Whole-Body Irradiation 17Filgrastim 15Radiotherapy 14Antilymphocyte Serum 14Tacrolimus 13Melphalan 13Gemcitabine 13Cyclosporine 13Busulfan 13Methotrexate 12Lenalidomide 12Bortezomib 12Bendamustine Hydrochloride 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10Cytarabine 10Doxorubicin 8Dexamethasone 8venetoclax 7thymoglobulin 7pembrolizumab 7Thiotepa 7Methylprednisolone 7Granulocyte Colony-Stimulating Factor 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Non-Hodgkin × Basiliximab × Clear all
NCT00594308 2014-10-06

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Indiana University

Phase NA Terminated
10 enrolled 11 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡